 SARASOTA, Fla., March 26, 2021 PRNewswire -- INVO Bioscience, Inc. NASDAQ: INVO, a medical device company focused on commercializing the worlds only in vivo Intravaginal Culture System IVC, INVOcell, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its fourth quarter and fiscal year 2020, ended December 31, 2020, after the market close on Tuesday, March 30, 2021. 